Double Cord Versus Haploidentical (BMT CTN 1101)



Status:Active, not recruiting
Conditions:Blood Cancer, Lymphoma, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:18 - 70
Updated:10/21/2018
Start Date:June 2012
End Date:June 2020

Use our guide to learn which trials are right for you!

A Multi-Center, Phase III, Randomized Trial of Reduced Intensity Conditioning (RIC) and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) Versus HLA-Haploidentical Related Bone Marrow (Haplo) for Patients With Hematologic Malignancies (BMT CTN #1101)

Hematopoietic cell transplants (HCT)are one treatment option for people with leukemia or
lymphoma. Family members,unrelated donors or banked umbilical cordblood units with similar
tissue type can be used for HCT. This study will compare the effectiveness of two new types
of bone marrow transplants in people with leukemia or lymphoma: one that uses bone marrow
donated from family members with only partially matched bone marrow; and, one that uses two
partially matched cord blood units.

Reduced intensity conditioning (RIC) blood or marrow transplantation (BMT) has allowed older
and less clinically fit patients to receive potentially curative treatment with allogeneic
HCT for high risk or advanced hematological malignancies. Patients lacking an HLA-matched
sibling may receive a graft from a suitably HLA-matched unrelated donor. However, up to a
third of patients will not have an HLA-matched sibling or a suitably matched adult unrelated
donor (i.e., no more than a mismatch at a single locus). Even when a suitably matched
unrelated donor is identified, data from the National Marrow Donor Program (NMDP) indicate
that a median of four months is required to complete searches that result in transplantation;
thus, some number of patients succumb to their disease while awaiting identification and
evaluation of a suitably matched adult unrelated donor.

Single or dual center studies have shown that partially HLA-mismatched related bone marrow
(haplo-BM) and unrelated double umbilical cord blood (dUCB) are valuable sources of donor
cells for RIC HCT, thus extending this treatment modality to patients who lack other donors.
In order to study the reproducibility, and thus, the wider applicability of these two
alternative donor strategies, The Blood and Marrow Transplantation Clinical Trials Network
(BMT CTN) conducted two parallel multicenter prospective Phase II clinical trials. These two
studies evaluated the safety and efficacy of related haplo-BM (BMT CTN 0603) and dUCB (BMT
CTN 0604) transplantation after RIC. Both of these alternative donor approaches produced
early results similar to that reported with unrelated donor, and even HLA-matched sibling,
HCT. These data demonstrate not only the efficacy of both of these approaches, but also that
both can be safely exported from the single center setting. Both haplo-BM and dUCB grafts can
be obtained rapidly for greater than 90% of patients lacking an HLA-matched donor. This study
will test the hypothesis that progression free survival at two years after RIC haplo-BM
transplantation is similar to the progression free survival after RIC dUCB transplantation.

Inclusion Criteria:

- Patients 18 to 70 years old

- Patients must have available both: a)One or more potential related mismatched donors
(biologic parent(s) or siblings (full or half) or children). At least low resolution
DNA based human leukocyte antigen (HLA) typing at HLA-A, -B, and -DRB1 for potential
haploidentical sibling donors is required. b)At least two potential umbilical cord
blood units identified. Each unit must have a minimum of 1.5 x 10^7/kg
pre-cryopreserved total nucleated cell dose. For non-red blood cell depleted units,
the minimum pre-cryopreserved total nucleated cell dose of each unit must be at least
2.0 x 10^7/kg. Units must be HLA matched at a minimum of 4/6 to the recipient at
HLA-A, HLA-B (at low resolution using DNA based typing) and HLA-DRB1 (at high
resolution using DNA based typing). Confirmatory typing is not required for
randomization.

- Acute Lymphoblastic Leukemia (ALL) in first complete remission (CR1) that is NOT
considered favorable-risk as defined by the presence of at least one of the following:
Adverse cytogenetics such as t(9;22), t(1;19), t(4;11), other Mixed Lineage Leukemia
(MLL) rearrangements; White blood cell counts of greater than 30,000/mcL (B-ALL) or
greater than 100,000/mcL (T-ALL)at diagnosis; Recipient age older than 30 years at
diagnosis; Time to CR greater than 4 weeks

- Acute Myelogeneous Leukemia (AML) in CR1 that is NOT considered as favorable-risk.
Favorable risk is defined as having one of the following: t(8.21) without CKIT
mutation, inv(16) without CKIT mutation or t(16;16), normal karyotype with mutated
NPM1 and not FLT-ITD, normal karyotype with double mutated CEBPA, Acute promyelocytic
leukemia (APL) in first molecular remission at end of consolidation

- Acute Leukemias in 2nd or subsequent CR

- Biphenotypic/Undifferentiated/Prolymphocytic Leukemias in first or subsequent CR,
adult T-cell leukemia/lymphoma in first or subsequent CR

- Burkitt's lymphoma: second or subsequent CR

- Lymphoma fulfilling the following criteria: Chemotherapy-sensitive (at least stable
disease lymphomas that have failed at least 1 prior regimen of multi-agent
chemotherapy and are INELIGIBLE for an autologous transplant. Patients with chronic
lymphocytic leukemia (CLL) are not eligible regardless of disease status.

- Performance status: Karnofsky score greater than or equal to 70%.

Additional Patient Inclusion Criteria for Conditioning:

- Patients with Adequate Physical Function as Measured by: a. Cardiac: Left ventricular
ejection fraction at rest must be greater than or equal to 40%, or shortening fraction
less than 25%; b. Hepatic: Bilirubin less than or equal to 2.5 mg/dL, except for
patients with Gilbert's syndrome or hemolysis. Alanine aminotransferase (ALT),
aspartate aminotransferase (AST), and Alkaline Phosphatase less than 5 x upper limit
of normal; c. Renal: Serum creatinine within normal range, or if serum creatinine
outside normal range, then renal function (measured or estimated creatinine clearance
or GFR)greater than 40 mL/min/1.73m^; d. Pulmonary: Diffusing capacity of the lung for
carbon monoxide (DLCO) (corrected for hemoglobin), forced expiratory volume in one
second (FEV1), and forced vital capacity (FVC) greater than 50% predicted;

- Additional Patient Inclusion Criteria for Patients Assigned to Haploidentical BM Arm:
Patients must be HLA typed at high resolution using DNA based typing at the following
HLA-loci: HLA-A, -B, -C and DRB1 and have available a related haploidentical BM donor
with 2, 3, or 4 HLA-mismatches. A unidirectional mismatch in either the graft versus
host or host versus graft direction is considered a mismatch. The donor and recipient
must be HLA identical for at least one antigen (using high resolution DNA based
typing) at the following genetic loci: HLA-A, HLA-B, HLA-C, and HLA-DRB1. Fulfillment
of this criterion shall be considered sufficient evidence that the donor and recipient
share one HLA haplotype, and typing of additional family members is not required.

- Additional Patient Inclusion Criteria for Patients Assigned to Double Umbilical Cord
Blood Arm:

1. Patients must have available two UCB units fulfilling the following criteria:

1. Each unit must have a minimum of 1.5 x 10^7/kg pre-cryopreserved total
nucleated cell dose. For non-red blood cell depleted units, the minimum
pre-cryopreserved total nucleated cell dose of each unit must be at least
2.0 x10^7/kg.

2. Units must be HLA matched at a minimum of 4/6 to the recipient at HLA -A,
HLA-B (at low resolution using DNA based typing), and HLA -DRB1 (at high
resolution using DNA based typing).

3. Additional graft selection criteria specified in section 2.5

2. Patients must have received at least one cycle of the cytotoxic chemotherapy
regimens (or regimen of similar intensity) listed in Appendix D within 3 months
of enrollment (measured from the start date of chemotherapy) OR have had an
autologous transplant within 24 months of enrollment OR receive 300 cGy as part
of the preparative regimen

Exclusion Criteria:

- Patients with suitably matched related or unrelated donor, as defined per
institutional practice.

- Recipients of prior autologous hematopoietic stem cell transplantation are ineligible
if disease recurrence occurred less than 6 months from their autologous stem cell
transplant.

- Current uncontrolled bacterial, viral or fungal infection (currently taking medication
with evidence of progression of clinical symptoms or radiologic findings).

- Prior allogeneic HCT.

- Patients with history of primary idiopathic myelofibrosis or any severe marrow
fibrosis.

- Planned use of prophylactic donor lymphocyte infusion (DLI) therapy.

- Anti-donor HLA antibodies.

Additional exclusion criteria:

- Pregnancy or breast-feeding.

- Evidence of HIV infection or known HIV positive serology.
We found this trial at
43
sites
1100 Fairview Avenue North
Seattle, Washington 98109
(206) 667-5000
Fred Hutchinson Cancer Research Center At Fred Hutchinson Cancer Research Center, our interdisciplinary teams of...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
201 Dowman Dr
Atlanta, Georgia 30303
(404) 727-6123
Emory University Emory University, recognized internationally for its outstanding liberal artscolleges, graduate and professional schools,...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
3400 N Charles St
Baltimore, Maryland 21205
410-516-8000
Johns Hopkins University The Johns Hopkins University opened in 1876, with the inauguration of its...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
1720 2nd Ave S
Birmingham, Alabama 35233
(205) 934-4011 
Phone: 205-975-7664
University of Alabama at Birmingham The University of Alabama at Birmingham (UAB) traces its roots...
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
(716) 845-2300
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
1600 SW Archer Rd # M509
Gainesville, Florida 32610
Phone: 352-273-8022
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
Los Angeles, California 90095
310-825-4321
University of California at Los Angeles The University of California, Los Angeles (UCLA) is an...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Miami, Florida 33124
(305) 284-2211
University of Miami A private research university with more than 15,000 students from around the...
?
mi
from
Miami, FL
Click here to add this to my saved trials
1211 Medical Center Dr
Nashville, Tennessee 37232
(615) 322-5000
Vanderbilt Univ Med Ctr Vanderbilt University Medical Center (VUMC) is a comprehensive healthcare facility dedicated...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
601 Elmwood Avenue
Rochester, New York 14642
(585) 275-2100
Univ of Rochester Medical Center One of the nation's top academic medical centers, the University...
?
mi
from
Rochester, NY
Click here to add this to my saved trials
Ann Arbor, Michigan 48109
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Atlanta, Georgia 30342
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Boston, Massachusetts 02114
?
mi
from
Boston, MA
Click here to add this to my saved trials
Boston, Massachusetts 02114
Phone: 617-632-5946
?
mi
from
Boston, MA
Click here to add this to my saved trials
101 Manning Dr
Chapel Hill, North Carolina 27599
(919) 966-4131
Phone: 919-966-7313
University of North Carolina Hospital at Chapel Hill The UNC Health Care System is a...
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
843-792-1414
Phone: 843-792-4271
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
?
mi
from
Charleston, SC
Click here to add this to my saved trials
Cincinnati, Ohio 45236
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cleveland, Ohio 44106
Phone: 216-844-3629
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
2049 E 100th St
Cleveland, Ohio 44106
(216) 444-2200
Phone: 216-444-3705
Cleveland Clinic Foundation The Cleveland Clinic (formally known as The Cleveland Clinic Foundation) is a...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Columbus, Ohio 43210
Phone: 614-293-8197
?
mi
from
Columbus, OH
Click here to add this to my saved trials
1721 East 19th Ave., Suite #200 & #300
Denver, Colorado 80218
720-754-4800
Colorado Blood Cancer Institute When patients come to the Colorado Blood Cancer Institute, the entire...
?
mi
from
Denver, CO
Click here to add this to my saved trials
Detroit, Michigan 48201
?
mi
from
Detroit, MI
Click here to add this to my saved trials
1500 East Duarte Road
Duarte, California 91010
626-256-HOPE (4673)
Phone: 626-256-4673
City of Hope National Medical Center City of Hope is dedicated to making a difference...
?
mi
from
Duarte, CA
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
919-684-8111
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
?
mi
from
Durham, NC
Click here to add this to my saved trials
?
mi
from
Hershey, PA
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
Kansas City, Kansas 66160
Phone: 913-588-6029
?
mi
from
Kansas City, KS
Click here to add this to my saved trials
Lexington, Kentucky
859) 257-9000
University of Kentucky The University of Kentucky is a public, land grant university dedicated to...
?
mi
from
Lexington, KY
Click here to add this to my saved trials
8701 W Watertown Plank Rd
Milwaukee, Wisconsin
(414) 955-8296
Phone: 414-805-0700
Medical College of Wisconsin The Medical College (MCW) of Wisconsin is a major national research...
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Minneapolis, Minnesota 55414
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Morgantown, West Virginia 26506
(304) 293-0111
West Virginia University West Virginia University, founded in 1867, has a long and rich history...
?
mi
from
Morgantown, WV
Click here to add this to my saved trials
New York, New York 10029
?
mi
from
New York, NY
Click here to add this to my saved trials
Oklahoma City, Oklahoma 73104
Phone: 405-271-4022
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Orlando, Florida 32804
Phone: 407-303-2091
?
mi
from
Orlando, FL
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phoenix, Arizona
Phone: 520-626-9526
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Phoenix, Arizona 85054
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Richmond, Virginia 23298
(804) 828-0100
Phone: 804-828-4360
Virginia Commonwealth University Since our founding as a medical school in 1838, Virginia Commonwealth University...
?
mi
from
Richmond, VA
Click here to add this to my saved trials
200 First Street SW
Rochester, Minnesota 55905
507-284-2511
Mayo Clinic Rochester Mayo Clinic is a nonprofit worldwide leader in medical care, research and...
?
mi
from
Rochester, MN
Click here to add this to my saved trials
San Antonio, Texas 78229
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
Stanford, California 94305
?
mi
from
Stanford, CA
Click here to add this to my saved trials
101 Nicolls Rd
Stony Brook, New York 11794
(631) 444-4000
Phone: 631-444-3577
Stony Brook University Medical Center Stony Brook Medicine expresses our shared mission of research, clinical...
?
mi
from
Stony Brook, NY
Click here to add this to my saved trials
1 Medical Center Blvd
Winston-Salem, North Carolina 27157
336-716-2011
Wake Forest University Health Sciences Welcome to Wake Forest Baptist Medical Center, a fully integrated...
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials